Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma

PURPOSE: Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established. MATERIALS AND METHODS: Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institution...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Res Treat
Main Authors: Cha, Yongjun, Kim, Yu Jung, Lee, Se-Hoon, Kim, Tae-Min, Choi, Seung Hong, Kim, Dong-Wan, Park, Chul-Kee, Kim, Il Han, Kim, Jee Hyun, Kim, Eunhee, Choi, Byungse, Kim, Chae-Yong, Kim, In Ah, Heo, Dae Seog
פורמט: Artigo
שפה:Inglês
יצא לאור: Korean Cancer Association 2017
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5266387/
https://ncbi.nlm.nih.gov/pubmed/27188199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2015.466
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים